VNDA Rasio cepet Vanda Pharmaceuticals

Vanda Pharmaceuticals (VNDA) relies on creating a closed-loop therapy cycle for sleep and mental disorders, utilizing unique patient support programs. The business is based in a defensive sector with low economic cycle sensitivity, where patents play a key role. The current metric is 1.63. This chart of the market valuation complements data on diversified drug supply channels through specialized networks.

Quick liquidity determines a company's ability to instantaneously settle its obligations without liquidating inventory. By analyzing the quick ratio, an investor assesses the relationship between cash and accounts receivable relative to short-term debt. This metric excludes low-liquidity assets, revealing the actual margin of financial strength. For Vanda Pharmaceuticals (VNDA), such resilience is critical, supporting the development of innovative drugs for the treatment of schizophrenia and sleep disorders.